New Treatments & Clinical Trials for Dermatomyositis

Dermatomyositis causes muscle weakness and a distinctive skin rash, often appearing on the face, knuckles, and chest. It affects about 10 people per million each year, more often women than men. Treatment typically starts with corticosteroids, then adds immunosuppressants like methotrexate or azathioprine to reduce steroid dependence and control the disease.

What's actually going on in research

Trials are testing JAK inhibitors that have worked in other autoimmune diseases, B-cell depleting drugs like rituximab, and newer targeted therapies including CAR T-cell approaches. Researchers are also studying biomarkers to predict who will respond to specific treatments and investigating the link between dermatomyositis and underlying cancers.

What to know before you search

Eligibility typically depends on disease activity (muscle strength testing and skin severity), antibody type, prior treatments tried, and whether cancer screening is up to date.

What types of trials are currently open

• Treatment trials — Testing new immunosuppressive drugs or biologics to see if they control muscle and skin symptoms better than standard medications like prednisone and methotrexate.
• Steroid-sparing trials — Studies of drugs that might allow people to reduce or stop corticosteroids while keeping symptoms controlled.
• Skin-focused trials — Testing treatments specifically for the rash and skin damage, which sometimes persists even when muscle symptoms improve.
• Biomarker studies — Collecting blood and muscle tissue to identify patterns that predict who will respond to specific treatments.
• Long-term follow-up studies — Tracking people with dermatomyositis over years to understand disease progression, cancer risk, and long-term treatment effects.